Insider Trading Activity Cytokinetics, Incorporated (NASDAQ:CYTK) – CEO Sold 5,000 shares of Stock

Insider Trading Activity For Cytokinetics, Incorporated (NASDAQ:CYTK)

Robert I Blum , CEO of Cytokinetics, Incorporated (NASDAQ:CYTK) reportedly Sold 5,000 shares of the company’s stock at an average price of 13.79 for a total transaction amount of $68,950.00 SEC Form

Insider Trading History For Cytokinetics, Incorporated (NASDAQ:CYTK)

On 2/25/2014 Eastern Capital Ltd, major shareholder, bought 500,000 with an average share price of $8.00 per share and the total transaction amounting to $4,000,000.00.View SEC Filing

On 5/9/2014 L Patrick Gage, Director, bought 10,850 with an average share price of $4.09 per share and the total transaction amounting to $44,376.50.View SEC Filing

On 12/30/2014 Fady Ibraham Malik, SVP, sold 21,630 with an average share price of $6.73 per share and the total transaction amounting to $145,569.90.View SEC Filing

On 3/11/2015 Andrew A Wolff, CMO, sold 21,875 with an average share price of $7.80 per share and the total transaction amounting to $170,625.00.View SEC Filing

On 5/6/2015 L Patrick Gage, Director, bought 10,000 with an average share price of $5.71 per share and the total transaction amounting to $57,100.00.View SEC Filing

On 8/20/2015 L Patrick Gage, Director, bought 10,000 with an average share price of $6.55 per share and the total transaction amounting to $65,500.00.View SEC Filing

On 8/31/2015 L Patrick Gage, Director, bought 1,000 with an average share price of $6.95 per share and the total transaction amounting to $6,950.00.View SEC Filing

Analyst Ratings For Cytokinetics, Incorporated (NASDAQ:CYTK)
These are 9 Buy Ratings, 1 Strong Buy Rating .
The current consensus rating for Cytokinetics, Incorporated (NASDAQ:CYTK) is Buy (Score: 3.10) with a consensus target price of $21.40 , a potential (42.67% upside)

Analyst Ratings History For Cytokinetics, Incorporated (NASDAQ:CYTK)

• On 3/9/2016 J P Morgan Chase & Co Lower Price Target of rating Market Outperform with a price target of $16.00 to $14.00
• On 10/28/2016 Roth Capital Set Price Target of rating Buy with a price target of $22.00
• On 12/1/2016 JMP Securities Reiterated Rating Buy
• On 2/17/2017 Piper Jaffray Companies Reiterated Rating Overweight with a price target of $15.00
• On 2/17/2017 Needham & Company LLC Reiterated Rating Strong-Buy with a price target of $22.00
• On 2/17/2017 FBR & Co Reiterated Rating Outperform with a price target of $24.00
• On 3/23/2017 Rodman & Renshaw Reiterated Rating Buy with a price target of $25.00

Recent Trading Activity for Cytokinetics, Incorporated (NASDAQ:CYTK)
Shares of Cytokinetics, Incorporated closed the previous trading session at 15.00 up +0.70 4.90% with 467,972 shares trading hands.